Head-to-head evidence
IcoSema vs PB-119
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: GLP-1 receptor · full Type 2 Diabetes pipeline
IcoSema · Kyinsu
Marketed by Novo Nordisk
NCT05352815 · Phase 3 · completed
Participants were randomized 1:1 to IcoSema or active insulin icodec, but the study was open-label rather than blinded. The primary HbA1c endpoint was statistically significantly better with IcoSema, although HbA1c is a surrogate metabolic measure rather than a hard clinical endpoint.
PB-119
Developed by PegBio
NCT04504396 · Phase 3 · completed
This randomized, placebo-controlled trial kept participants, care providers, investigators and outcome assessors blind to treatment assignment. Its primary endpoint, change in HbA1c, was clearly met, with PB-119 producing a significantly larger reduction than placebo (P<0.001).
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: IcoSema's landscape · PB-119's landscape